July 14, 2023 SARC037 is Open and Accruing In a rare disease as Ewing sarcoma, we recognize we need to work together to complete important studies like this. Read more
January 3, 2023 proviDING hope for patients with osteosarcoma Derek Fadness was only the second patient in the nation to join this clinical trial. Read his remarkable story. Read more
May 9, 2022 SARC032 EXPANDED SU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. SARC032 … Read more
November 24, 2021 SARC Sets Goal to Raise Funds for Clinical Trial SARC042 Together we give. Giving Tuesday is on Tuesday, November 30. It is a designated day each year to encourage charitable giving to support those who need our help. By donating, … Read more
August 31, 2021 SARC024 Texas Children’s Cancer and Hematology Centers is now open to enrollment in SARC024 (Regorafenib/Refractory Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcomas). SARC024 sites include: • Atrium Health Levine Cancer Institute (Atlanta, GA)• … Read more
May 24, 2021 Understanding Adoptive Cell Therapy for Sarcoma Adoptive Cell Therapy is a type of cancer treatment that uses your own immune system to treat your cancer; it may be an option for patients with some types of … Read more
March 9, 2021 A message from SARC Medical Officer Scott Okuno: Open Clinical Trials Message (excerpt) from Dr. Okuno to SARC Members: SARC has several “open, active, enrolling clinical trials [including] extremity soft tissue sarcoma trial using radiation therapy and immunotherapy neoadjuvantly…for advanced metastatic … Read more
January 15, 2021 New Study in Ewing Sarcoma Open to Enrollment SARC037 is a phase I study protocol to determine the recommended dose of trabectedin given as a 1-hour infusion in combination with low dose irinotecan. All patients enrolled will receive trabectedin combination … Read more
December 1, 2020 Launch of Phase 2 Clinical Trial for Patients with Clear Cell Sarcoma of Soft Tissue SARC is proud to partner with Sara’s Cure and Rafael Pharmaceuticals for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear … Read more
November 30, 2020 Open Accruing SARC Studies Open accruing studies for you to refer or enroll your patients: SARC024 for Rhabdomyosarcoma (alveolar and embryonal) and Mesenchymal Chondrosarcoma SARC031 for Unresectable or Metastatic NF1 Associated or Sporadic Malignant Peripheral Nerve … Read more